This multi-year cohort study will assess the real-world safety and effectiveness of 1L treatment with cemiplimab in combination with platinum-doublet chemotherapy across advanced NSCLC patient subgroups defined by age, sex, race, and ethnicity. Patients will be retrospectively identified from at least two US electronic health record (EHR)-based databases.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Real-world response rate (rwRR)
Timeframe: Approximately 3 years
Any treatment-emergent immune-mediated adverse event (imAE)
Timeframe: Approximately 3 years
Any treatment-emergent imAE resulting in hospitalization
Timeframe: Approximately 3 years
Any treatment-emergent imAE resulting in death
Timeframe: Approximately 3 years
Specific treatment-emergent imAEs
Timeframe: Approximately 3 years